Legend Biotech (LEGN) Cash from Investing Activities (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Cash from Investing Activities data on file, last reported at -$168.0 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 165.47% year-over-year to -$168.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $285.0 million (up 244.05% YoY) and the FY2025 annual result came in at $709.6 million, up 183.42% from the prior year.
• Cash from Investing Activities eased to -$168.0 million in Q1 2026, from $638.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $638.5 million in Q4 2025 to a low of -$695.6 million in Q2 2024.
• A 5-year average of -$17.3 million and a median of -$20.0 million in 2025 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 1534.48% in 2023, down 4807.27% in 2023.
• Tracing LEGN's Cash from Investing Activities over 5 years: stood at $24.9 million in 2022, then surged by 1534.48% to $407.5 million in 2023, then slumped by 121.57% to -$87.9 million in 2024, then jumped by 826.39% to $638.5 million in 2025, then tumbled by 126.31% to -$168.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$168.0 million (Q1 2026), $638.5 million (Q4 2025), and -$20.0 million (Q3 2025), per Business Quant data.